TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33153578

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 4050

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 4050

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 4050

Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dl
Number of subjects: 4050
Study: 34767083

Group type: EXPERIMENTAL
Intervention: sEMG-biofeedback rehabilitation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 17
Study: 34903035

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) therapy
Number of subjects: 0
Study: 33579247

Group type: EXPERIMENTAL
Intervention: Coronal cleaning of palate and tongue
Number of subjects: 276

Group type: COMPARATOR
Intervention: Sagittal cleaning of palate and tongue
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Tolerable cleaning depth for palate
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Tolerable cleaning depth for tongue
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Participants with male sex and high BMI (overweight/obese)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Other discomforts reported by participants
Number of subjects: 276
Study: 35255859

Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC): nurse-led services for HIV testing plus ART if positive or PrEP for those eligible and negative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexual and Reproductive Health (SRH): Baseline self-collected vaginal and urine samples with study-organized clinic appointments for results, treatment and delivery of HIV testing, ART and PrEP integrated with SRH services
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer-support: Study referral of participants to a peer navigator to assess their health, social and educational needs and provide risk-informed HIV prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SRH + peer-support: Combination of SRH services and peer navigator support
Number of subjects: 0
Study: 35999562

Group type: EXPERIMENTAL
Intervention: Berberine and fenugreek co-supplementation (3 capsules/day of 500 mg: 300 mg of berberine + 200 mg of fenugreek seed powder) for 12 weeks
Number of subjects: 50
Study: 34712203

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea polyphenols (DGTP) 400 mg/day for 12 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Isodose placebo
Number of subjects: 62
Study: 33553662

Group type: EXPERIMENTAL
Intervention: Educational intervention by clinical pharmacists including training on IBS-related knowledge, medication adherence, lifestyle, and diet adjustments.
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard medical therapy (nonintervention group).
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (as part of the educational program).
Number of subjects: 273
Study: 33037036

Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI (2 mg)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Exenatide two times per day (5 mcg for 4 weeks, followed by 10 mcg for 28 weeks)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI (2 mg) continued for 52 weeks
Number of subjects: 315
Study: 35143603

Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase (0.225 mg/kg; maximum dose, 22.5 mg) infused over 15 to 30 minutes
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intra-arterial alteplase
Number of subjects: 121
Study: 33606922

Group type: COMPARATOR
Intervention: GSK3352589 single-dose (2 to 400 mg, including 25 mg food effect arm)
Number of subjects: 68

Group type: COMPARATOR
Intervention: GSK3352589 repeat-dose (5 to 200 mg, twice daily for 14 days with food)
Number of subjects: 68

Group type: COMPARATOR
Intervention: GSK3352589 (both single and repeat doses)
Number of subjects: 68
Study: 32297043

Group type: EXPERIMENTAL
Intervention: Urea at 40 g/kg DM
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Urea at 60 g/kg DM
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NaOH at 40 g/kg DM
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NaOH at 60 g/kg DM
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no chemical treatment)
Number of subjects: 7
Study: 35802515

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy for 3 months
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy for 3 months (adherent participants)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 148
Study: 33340229

Group type: EXPERIMENTAL
Intervention: Dermabrasion
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cryoblister
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dermaroller
Number of subjects: 36
Study: 32818766

Group type: EXPERIMENTAL
Intervention: S. viridis exposed to NaCl (50 mM) for 12 days
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: S. alterniflora exposed to NaCl (up to 550 mM)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: S. viridis under NaCl stress
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: S. alterniflora under NaCl stress
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RNA-seq analysis for S. viridis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: RNA-seq analysis for S. alterniflora
Number of subjects: 2
Study: 35920102

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg (FIL100)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) 40 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Long-term extension (LTE) filgotinib patients
Number of subjects: 147

Group type: COMPARATOR
Intervention: Long-term extension (LTE) ADA patients
Number of subjects: 147
Study: 34187829

Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care control (no PAP)
Number of subjects: 0
Study: 33461636

Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg/day
Number of subjects: 529

Group type: EXPERIMENTAL
Intervention: Asenapine 20 mg/day
Number of subjects: 529

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study: 34080890

Group type: EXPERIMENTAL
Intervention: Varenicline plus Naltrexone (2 mg/day of varenicline plus 50 mg/day of naltrexone)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Varenicline plus Placebo (2 mg/day of varenicline plus matched placebo)
Number of subjects: 165
Study: 32783585

Group type: EXPERIMENTAL
Intervention: Topical application of lidocaine/prilocaine (EMLA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pin electrode stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patch electrode stimulation
Number of subjects: 0
Study: 35908601

Group type: EXPERIMENTAL
Intervention: Active capacitive-resistive electrical therapy to the lower cervical region (C4-C7), twice weekly for a total of six treatments
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham (inactive) treatment
Number of subjects: 20
Study: 34161750

Group type: EXPERIMENTAL
Intervention: POD F‐GF group (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: POD F group (n = 50)
Number of subjects: 100
Study: 35391580

Group type: EXPERIMENTAL
Intervention: Online-supervised corrective exercises
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Workplace corrective exercises
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (usual activities)
Number of subjects: 36
Study: 34735441

Group type: EXPERIMENTAL
Intervention: Socio-emotional intervention (including 'Affect Dyad')
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (including 'Breathing Meditation')
Number of subjects: 300

Group type: COMPARATOR
Intervention: Retest control group
Number of subjects: 300
Study: 32224279

Group type: EXPERIMENTAL
Intervention: Exposure to 5 °C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to 10 °C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to 15 °C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aerial exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidant enzyme activities and T-AOC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative expression levels of Hsp90 and Hsp70 mRNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immune enzyme activities (ACP, AKP, LSZ, T-NOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gene expression of TLR, Rel, and p105
Number of subjects: 0
Study: 33411207

Group type: EXPERIMENTAL
Intervention: Computerized version of the inferential reading comprehension intervention
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Teacher-led version of the inferential reading comprehension intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Business-as-usual (BaU) control instruction
Number of subjects: 66
Study: 32389738

Group type: EXPERIMENTAL
Intervention: Topical tacalcitol plus 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 5‐aminolevulinic acid photodynamic therapy (ALA‐PDT) alone
Number of subjects: 21
Study: 33798311

Group type: EXPERIMENTAL
Intervention: Cupping treatment combined with antibiotics (cefodizine sodium 80 mg/(kg•d) for 7 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Antibiotics alone (cefodizine sodium 80 mg/(kg•d) for 7 days)
Number of subjects: 72
Study: 35248132

Group type: EXPERIMENTAL
Intervention: Low-dose ticagrelor combined with 100 mg aspirin
Number of subjects: 2090

Group type: COMPARATOR
Intervention: Standard-dose ticagrelor combined with 100 mg aspirin
Number of subjects: 2090
Study: 33555926

Group type: EXPERIMENTAL
Intervention: PEG + FOLFOX
Number of subjects: 567

Group type: COMPARATOR
Intervention: FOLFOX
Number of subjects: 567
Study: 35470972

Group type: EXPERIMENTAL
Intervention: DIET
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: DIET+MODPA
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: DIET+HIGHPA
Number of subjects: 383
Study: 32664052

Group type: EXPERIMENTAL
Intervention: Fex-Can intervention (web-based psycho-educational intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fex-Can intervention
Number of subjects: 0
Study: 34775578

Group type: EXPERIMENTAL
Intervention: AMP5A
Number of subjects: 40

Group type: COMPARATOR
Intervention: SOC (Control)
Number of subjects: 40
Study: 32573831

Group type: EXPERIMENTAL
Intervention: New competing-risks model based on maternal characteristics and medical history.
Number of subjects: 124443

Group type: COMPARATOR
Intervention: Logistic regression models for different SGA definitions.
Number of subjects: 124443
Study: 36257323

Group type: EXPERIMENTAL
Intervention: Pivot
Number of subjects: 188
Study: 33542037

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block III (QLB III)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Transversalis fascia plane block (TFPB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no regional nerve block)
Number of subjects: 90
Study: 35686998

Group type: EXPERIMENTAL
Intervention: Occasional cannabis use (1 or 2 times per week) after acute cannabis use
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Daily cannabis use after acute cannabis use
Number of subjects: 85

Group type: COMPARATOR
Intervention: No cannabis use
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Occasional cannabis use
Number of subjects: 85
Study: 34087057

Group type: EXPERIMENTAL
Intervention: Active smoking cessation service by respiratory physicians
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no active smoking cessation service)
Number of subjects: 250
Study: 36282451

Group type: EXPERIMENTAL
Intervention: Empowerment Program (EP), 5 weeks, one session of 20 to 30 minutes each week
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Empowerment Program (EP)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 70
Study: 34702439

Group type: EXPERIMENTAL
Intervention: Transtheoretical Model (TTM) intervention, including behavioral processes of change, self-efficacy, and decisional balance
Number of subjects: 414
Study: 32560639

Group type: COMPARATOR
Intervention: Intravitreal ranibizumab 0.5 mg alone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab 0.5 mg with macular laser
Number of subjects: 64
Study: 33836825

Group type: EXPERIMENTAL
Intervention: Germ Defence intervention via GP practices
Number of subjects: 11100000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 11100000
Study: 34807763

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Lamivudine (LAM) for 24 weeks followed by Tenofovir (TDF)
Number of subjects: 37
Study: 32048209

Group type: EXPERIMENTAL
Intervention: Liquid chromatography-mass spectrometry (LC–MS) and next-generation DNA sequencing
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Liquid chromatography-mass spectrometry (LC–MS)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Next-generation DNA sequencing
Number of subjects: 49
Study: 34756350

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 300mgkg-1 body weight, supplemented prior to (150mgkg-1) and during (150mgkg-1) a 3-h simulated cycling race.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 11

Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 11
Study: 32955601

Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 20 ml of 0.25% bupivacaine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mid-transverse to pleura (MTP) block with 20 ml of 0.25% bupivacaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study: 35144662

Group type: EXPERIMENTAL
Intervention: Opposing electroacupuncture group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham opposing electroacupuncture group
Number of subjects: 100
Study: 34118712

Group type: EXPERIMENTAL
Intervention: StaySafe app (12 weekly sessions)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Standard practice (SP)
Number of subjects: 511
Study: 32654362

Group type: EXPERIMENTAL
Intervention: Alternating cycles of sunitinib and everolimus (12 weeks each)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard sequential treatment of sunitinib followed by everolimus
Number of subjects: 41
Study: 36419181

Group type: EXPERIMENTAL
Intervention: IV ketamine (KET) 0.5 mg/kg over 40 min
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IM naltrexone (NTX) 380 mg once
Number of subjects: 44

Group type: COMPARATOR
Intervention: Linkage alone (LA)
Number of subjects: 44
Study: 32267019

Group type: EXPERIMENTAL
Intervention: Media reports not consistent with media recommendations
Number of subjects: 148

Group type: COMPARATOR
Intervention: Media reports consistent with media recommendations
Number of subjects: 148

Group type: COMPARATOR
Intervention: Articles about homicide (control group)
Number of subjects: 148
Study: 32677699

Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes in context A
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cigarettes in context B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine-containing cigarettes in context B
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo cigarettes in context A
Number of subjects: 40
Study: 33538413

Group type: EXPERIMENTAL
Intervention: Hypnosis intervention (HI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-hypnosis practice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control (WC)
Number of subjects: 40
Study: 33205924

Group type: EXPERIMENTAL
Intervention: FDS76® dental implant
Number of subjects: 0
Study: 32924897

Group type: EXPERIMENTAL
Intervention: Bright white light therapy (BLT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Dim red light (DRL)
Number of subjects: 93
Study: 33549453

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) of −700 kilocalories/day
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Caloric restriction combined with physical activity (CR&PA) of −500 kilocalories/day plus −200 kilocalories/day from PA
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group receiving a monthly motivational phone call
Number of subjects: 73
Study: 35168637

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 252

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 252
Study: 34191423

Group type: EXPERIMENTAL
Intervention: Exercise, essential amino acid (AA) ingestion, and tea catechin (TC) ingestion
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Exercise and essential AA ingestion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 84
Study: 35226080

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 180
Study: 33498894

Group type: EXPERIMENTAL
Intervention: Group-based intervention (Group 1, n = 36)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Individual-based intervention (Group 2, n = 30)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Website-based intervention (Group 3, n = 25)
Number of subjects: 115
Study: 32083500

Group type: EXPERIMENTAL
Intervention: Exergaming protocol using Xbox 360 Kinect® with the game Your Shape Fitness Evolved 2012, 2-3 times per week for 20 sessions.
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 38
Study: 35395069

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily (females subgroup)
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg daily (males subgroup)
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 33636417

Group type: EXPERIMENTAL
Intervention: 7-day fasting intervention
Number of subjects: 20
Study: 32125421

Group type: EXPERIMENTAL
Intervention: 240 ppm stevia beverage
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Caloric beverages (maltodextrin, glucose, sucrose)
Number of subjects: 20
Study: 35788383

Group type: EXPERIMENTAL
Intervention: Economic analyses in NCI grants
Number of subjects: 146
Study: 32579397

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair
Number of subjects: 35

Group type: COMPARATOR
Intervention: Open Latarjet procedure
Number of subjects: 35
Study: 35394711

Group type: EXPERIMENTAL
Intervention: Fat graft with I-PRF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fat graft only
Number of subjects: 20
Study: 33428673

Group type: COMPARATOR
Intervention: Acoustic brain entrainment (ABE) using frequency-modified music (400 and 418 Hz) during driving for 20 minutes.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acoustic brain entrainment (ABE) during driving for 20 minutes.
Number of subjects: 80
Study: 616037810

Group type: EXPERIMENTAL
Intervention: Centurion Vision System
Number of subjects: 101

Group type: COMPARATOR
Intervention: Infiniti Vision System
Number of subjects: 101
Study: 34495754

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 61

Group type: COMPARATOR
Intervention: Nonabsorbable sutures
Number of subjects: 61
Study: 35644071

Group type: EXPERIMENTAL
Intervention: Flumazenil (4 mg/24 h for approximately eight days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 32587298

Group type: EXPERIMENTAL
Intervention: DiMAL 0.1 mM
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: DiMAL 0.6 mM
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: IPC
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: DiMAL
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 2
Study: 34116204

Group type: EXPERIMENTAL
Intervention: EPCO patients (excluded from PIRATE trial)
Number of subjects: 405

Group type: COMPARATOR
Intervention: PIRATE patients (included in the trial)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Excluded patients for non-medical reasons
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: EPCO patients with different treatment durations
Number of subjects: 405
Study: 33768537

Group type: EXPERIMENTAL
Intervention: JASPER intervention (Joint Attention, Symbolic Play, Engagement, and Regulation) delivered by educators in the community.
Number of subjects: 179

Group type: COMPARATOR
Intervention: Waitlist control (treatment as usual).
Number of subjects: 179
Study: 35422402

Group type: EXPERIMENTAL
Intervention: Automated segmentation using 2D U-Net architecture on sagittal images
Number of subjects: 57

Group type: COMPARATOR
Intervention: Manual digitization
Number of subjects: 57
Study: 32673102

Group type: EXPERIMENTAL
Intervention: Interactive Videogames Group (IVG) - Nintendo Wii Sports (tennis, golf, boxing, bowling), 14 sessions, 50 minutes each, mild to moderate intensity
Number of subjects: 39

Group type: COMPARATOR
Intervention: Active Exercises Group (AEG) - Similar movements to IVG, 14 sessions, 50 minutes each, mild to moderate intensity
Number of subjects: 39
Study: 35122297

Group type: EXPERIMENTAL
Intervention: Way Back Support Service (WBSS) - a non-clinical after-care program for 3 months following a hospital-treated suicide attempt.
Number of subjects: 2770
Study: 34403293

Group type: EXPERIMENTAL
Intervention: Systematic feedback and discussion of patient-reported outcomes (PRO) during consultation
Number of subjects: 279

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 279
Study: 33305386

Group type: EXPERIMENTAL
Intervention: Intervention group (online intervention for psychosis)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 124
Study: 34455630

Group type: EXPERIMENTAL
Intervention: Soaking for 3 minutes
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Soaking for 5 minutes
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Soaking for 10 minutes
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Soaking for 15 minutes
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Soaking for 20 minutes
Number of subjects: 65